In conclusion, out study revealed baseline, trend, and normalization of CEA are potential prognostic markers in EGFR-mutant NSCLC patients treated with first-line EGFR-TKI therapy. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.